Sandip B. Ahire /Afr.J.Bio.Sc. 6(13) (2024)

ISSN: 2663-2187

https://doi.org/10.48047/AFJBS.6.13.2024.6613-6621



# FORMULATION AND DEVELOPMENT OF SUSTAINED RELEASE TABLET OF BCS CLASS III DRUG BY USING NATURAL POLYMER

#### Sandip B. Ahire, Momin Abuzer\*, Pratik D. Patil, Vinod A. Bairagi, A.B. Gangurde, Osama Tauseef,

#### Rahil khan, Ansari Mohammed Shoaib

K.B.H.S.S. Trust's Institute of Pharmacy, Malegaon Dist. Nashik Maharashtra (India)

Email id: mominabuzer764@gmail.com

Volume 6, Issue 13, Aug 2024 Received: 15 June 2024

Accepted: 25 July 2024

Published: 15 Aug 2024

doi: 10.48047/AFJBS.6.13.2024.6613-6621

#### ABSTRACT

Tablet.

The development of sustained release tablets for BCS Class III drugs, which are characterized by high solubility and low permeability, presents a unique challenge in pharmaceutical formulation. This study aims to formulate and develop a sustained release tablet utilizing natural polymers, focusing on enhancing the drug's bioavailability and therapeutic efficacy. Natural polymers offer several advantages, including biocompatibility, biodegradability, and minimal side effects, making them ideal candidates for sustained release formulations. The research involves the selection and characterization of Bhara Gum and Gum Karaya, formulation development, and comprehensive evaluation of the tablet's physical and chemical properties. Key parameters such as drug release profile, dissolution rate, and stability are assessed to ensure consistent and prolonged drug release. The goal is to achieve a formulation that provides sustained therapeutic action, reduces dosing frequency, and enhances patient compliance. This study contributes to the growing field of natural polymer applications in drug delivery systems, offering potential for improved treatment outcomes for BCS Class III drugs. **Keywords:** Metformin, Sustained release, Bhara gum, Gum Karaya, Matrix

## INTRODUCTION

Sustained release dosage forms seek to create a longer therapeutic impact by releasing the medicine over an extended period of time. This therefore makes it possible to lower the overall dosage of the medication given as wellas the frequency of negative side effects (1). Which in turn improves patient compliance. On the other hand, matrix systems refer to those in which the medicine is evenly dissolved or distributed within a substance that delays its release. These systems can be designed as bi- or tri-layered matrix systems, (2). Standard matrix systems, or in a matrix system, the active and inactive components are combined and uniformly distributed throughout the dosage form (3)<sup>o</sup>

**Natural gums** Because they are inexpensive, environmentally friendly, safe, non-toxic, biocompatible, biodegradable, and plentiful in nature, Natural excipients are preferredover synthetic ones, as gums are often pathological by products resulting from plant damage or poor growing conditions. These are the aberrant by products of plant metabolism, thus. "Gummosis" is the term for the process. It's likely that gum originated from the

natural plant exudates that seeped out of tree bark. Palants create transparent, amorphous substances called gums. Gums can dissolve in water completely or partially.Most organic solvents and alcohol do not dissolve them. When combined with water, they either swell or absorb water, forming viscous sticky solutions. Typically, an aqueous gum solution is laevorotary; they are Guar gum, gum ghatti, tragacanth, gum acacia, and gum are significant gums in the pharmaceutical industry. Neem chewing gum Moringa leaf. In general, gums are employed mostly in the printing, textile, paper, paint, confectionery, food, and pharmaceutical sectors as thickening agents or adhesives. They serve as stabilisers, thickening agents, emulsifiers, suspending agents, and tablet binding agents.

There are three main types of gums: modified gums, synthetic gums, and natural gums.

**Natural gums:** These come from extracts of some legume seeds, seaweed hydrocolloids, or tree exudates in their natural condition. Examples include neem gum, tragacanth, moringa gum, and Arabica gum.

**Modified gums:** They are natural gums that have undergone chemical modification or are made from substances that are found naturally, such starch or cellulose. For example, carboxymethylcellulose.

**Synthetic Gums:** These are entirely artificial chemical compounds. For example, polyethylene oxide and polyvinyl pyrrolidone (5).

### MATERIALS AND METHODS

#### Metformin hydrochloride

Metformin HCI is a biguanide-type drug used along with a diet and exercise program to control high blood sugar in patients with type 2 diabetes. Controlling high blood sugar helps prevent heart disease, strokes, kidney disease, blindness, circulation problems, and sexual function problems. To reduce frequency of administration and to improve patient compliance, a sustain release formulation is required.

**Materials:** Metformin Hydrochloride Bhara gum, Gum Karaya Magnesium stearate, Talc, Starch, ethyl cellulose, Microcrystalline Cellulose,

| Ingredient      | F1   | F2   | F3   | F4   | F5   | F6   |
|-----------------|------|------|------|------|------|------|
|                 | (mg) | (mg) | (mg) | (mg) | (mg) | (mg) |
| Metformin HCL.  | 500  | 500  | 500  | 500  | 500  | 500  |
| Bhara Gum       | 90   | 135  | 180  | -    | -    | -    |
| Gum Karaya      | -    | -    | -    | 90   | 135  | 180  |
| Carrageenan     | 184  | 139  | 94   | 184  | 139  | 94   |
| Talc            | 18   | 18   | 18   | 18   | 18   | 18   |
| Ethyl Cellulose | 36   | 36   | 36   | 36   | 36   | 36   |
| Magnesium       | 18   | 18   | 18   | 18   | 18   | 18   |
| Stearate        |      |      |      |      |      |      |
| Chitosan        | 36   | 36   | 36   | 36   | 36   | 36   |
| Starch          | 18   | 18   | 18   | 18   | 18   | 18   |
|                 | 900  | 900  | 900  | 900  | 900  | 900  |

#### Table 1 Formulation study and development of trial batches

Sandip B. Ahire /*Afr.J.Bio.Sc.* 6(13) (2024)

Page 6615 of 9

#### Method of preparation of sustained release tablet of Metformin HCL:

The sustained release tablet of Metformin Hydrochloride was formulated by using wet Granulation method (6,7). The active ingredient was passed through the sieve#40 followed by the other ingredients were passed the same sieve. Metformin Hydrochloride, Carrageenan, (8,9). Chitosan, Bhara gum, Gum karaya, Ethyl cellulose, and Micro crystalline cellulose were taken in a poly bag according to the formulation table and mixed for 5minutes to ensure uniform mixing of the ingredients with the drug (10,11). Weigh Starch accurately (22) and it is mixed with water to form a paste is used as binder solution and kept separately (12, 13). The binder solution was added slowly to the dry mixed ingredients with constant mixing till to get solid mass to form uniform and optimum granules (14, 15). Then the wet granules were dried in trays and pass the air for drying Samples were removed randomly at different time intervals from the total bulk of the granules and then checked out for moisture content (16, 17). The dried materials were passed through the sicvc#20. After sieving dry granules were lubricated using Magnesium stearate and Talc (18, 19). After lubrication granules were sent to compression. Metformin Hydrochloride tablets was compressed using 12mm round punch (20, 21).

#### **Evaluation of Metformin Hydrochloride Tablets**

**Appearance:** The thickness of tablet and dimensional variable was evaluated. The tablet thickness was controlled within average value. The colour, odour, texture are other important characteristics were observed **Hardness:** Tablet Tester Tablet requires certain amount of mechanical strength or hardness, which was measured by Monsanto Hardness Tester. Ten tablets were randomly picked from batch formulation batch and evaluated for hardness during manufacturing and expressed in Kg/cm<sup>2</sup>. For each batch five tablets were used **Thickness:** The thickness of tablet and diameter were measured by digital Vernier calliper apparatus. **Friability:** The 10 reweighed tablets were placed in the Roche friabilator, which were then perated for 100 revolutions (25 rpm). The tablets were then dusted and reweighed. The tablets dukes less than 1.0% of their weights are generally considered acceptable

Friability = [1 - (Wt. /W)] \* 100 Where,

F friability in percentage

W = initial weight of tablet,

Wt. = weight of tablet after friability

**Weight Variation test:** To study weight variation test according to IP the test was run by weighing 20 tablets individually, calculating the average weight, and comparing the individual tablet weight to the average.

| Average weight of tablet (mg) | Maximum percent difference |
|-------------------------------|----------------------------|
|                               | allowed                    |
| 80 or less                    | 10%                        |
| 80-250                        | 7.5%                       |
| 250 or more                   | 5%                         |

**Uniformity in Drug Content:** From each batch of prepared tablets, five tablets were collected randomly and powdered. A quantity of powder equivalent to 250 mg was transferred to 100 ml volumetric flask. 10 ml of 0.1 N HCL was added and then the solution was subjected to sonication for 10 min. The solution was made up to 100 ml with 0.1 N HCL. The solution was filtered and suitable dilutions were prepared with 0.1 N HCL and then the drug content was estimated by recording absorbance at 239 nm by using UV- spectrophotometer.

**Dissolution study:** The in vitro release of dissolution studies from the formulated tablets was carried out in Tablet dissolution tester USP- Electro lab USP-TOT-081, using 900 ml of dissolution medium maintained at  $37.0 + 0.5^{\circ}$ C at a stirring rate of 50 rpm. One tablet from each formulation were rested individually in 0.1 N HCL for the first 2 hr. and in phosphate buffer (pH 6.8) for the following 10 hr. Samples measuring 5 ml were withdrawn at different time intervals such as 15 min 30 min, 1 hr.2 hr. During sampling samples were filtered through 10 um filter. The fresh dissolution medium (37 C) was replaced every time with the same quantity of the sample Collected Samples were suitably diluted with purified water and analyzed at 233 nm using 0.1 N HCL as blank. Dissolution is continued till 12 hr. by withdrawn sample at 3 to 12 hours by following the same procedure by using pH 6.8phosphate buffer as the cumulative percentage drug release was calculated.

#### **RESULT AND DISCUSSION**

#### **Pre-formulation Study**

**Organoleptic Properties of natural gum:** The organoleptic characteristics of Bhara gum and Gum karaya like state, colour, odour and taste were studied as shown in following table.

| Parameter | Bhara gum   | Gum karaya    |
|-----------|-------------|---------------|
| State     | Translucent | Translucent   |
| Colour    | Yellowish   | White or pale |
| Odour     | Myrtales    | odourless     |
| Taste     | Tasteless   | Tasteless     |

 Table 3 Organoleptic characteristics of Bhara gum and Gum karaya

#### Physicochemical evaluation of Bhara gum and Gum karaya Table 4 Evaluation of gum

| Parameter                 | Bhara gum | Gum karaya |  |
|---------------------------|-----------|------------|--|
| Bulk density (g/ml)       | 0.59      | 0.30       |  |
| Tapped density (g/ml)     | 0.86      | 0.98       |  |
| Angle of repose (0)       | 23        | 38.73      |  |
| Compressibility index (%) | 17.66     | 10.55      |  |
| Swelling index            | 7.4       | 1.02       |  |
| Loss on drying (% w/w)    | 3.96      | 4.5        |  |
| Total ash (% w/w)         | 5.8       | 2.2        |  |
| рН                        | 4.8       | 4 - 8      |  |

## Preformulation study of Metformin Hydrochloride

## Organoleptic properties of Metformin Hydrochloride

The organoleptic characteristics of drug like colour, odour and taste were studied as shown in following table.

| Parameter | Observation     |
|-----------|-----------------|
| Colour    | White-off-white |
| Odour     | Characteristic  |
| Taste     | Bitter          |

Table 5 Organoleptic Characteristics of Drug

FTIR Studies:

Infra-red spectroscopy is one of the most powerful analytical techniques to identify functional groups of drugs. IR spectroscopy was conducted using a FTIR and the spectrum was recorded wavelength region 4000-400cm. The procedure consisted of disappearing a sample alone. The sample was placed in light path in sample holder and the spectrum was recorded. The FTIR spectrum of drug shown in figure. The peaks observed in figure are listed in table and can be considered as characteristics peaks of each sample. These peaks were compared with the individual peaks. (12). The IR spectra of drug and polymers (Bhara gum & Gum karaya) were recorded in combination with each other's.




Figure 2 IR Spectrum of Metformin Hydrochloride

| Functional group                | Observed frequency (cm <sup>1</sup> ) | Stretching/ Deformation |  |
|---------------------------------|---------------------------------------|-------------------------|--|
| -NH Amine (3550-3250            | 3368.23                               | Stretching              |  |
| ()-H (3500-3200)                | 3148.15                               | Stretching              |  |
| -NH deformation (1650-<br>1581) | 1621.05                               | Deformation             |  |
| -CN Stretching (1170-<br>1040)  | 1059.68                               | Stretching              |  |
| -CN Stretching (1170-<br>1040)  | 935.94                                | Stretching              |  |
| = C-H (1000-650)                | 735.91                                | Bending                 |  |

Table 7 Absorbance of Metformin Hydrochloride in Distilled Water

| Concentration in PPM            | Absorbance |       |       |                        |  |  |
|---------------------------------|------------|-------|-------|------------------------|--|--|
|                                 | Ι          | II    | III   | Mean                   |  |  |
| 02                              | 0.214      | 0.289 | 0.31  | 0.271                  |  |  |
| 04                              | 0.518      | 0.518 | 0.53  | 32 0.522               |  |  |
| 06                              | 0.740      | 0.808 | 0.78  | .779                   |  |  |
| 08                              | 1.004      | 1.020 | 1.04  | 1.024                  |  |  |
| 10                              | 1.229      | 1.292 | 1.40  | 08 1.309               |  |  |
| 12                              | 1.554      | 1.541 | 1.60  | )2 1.565               |  |  |
| Co-efficient of Correlation(r2) |            |       | 0.998 | <b>,</b>               |  |  |
| Equation of Line (y=mx+c)       |            |       | Y=0.0 | $0737 \times + 0.0628$ |  |  |





Figure 3 Calibration Curve of Metformin Hydrochloride in Distilled Water


| Formulation | Weight    | Hardness(kg | Thickness | Friability | Drug    |
|-------------|-----------|-------------|-----------|------------|---------|
| code        | variation | / cm2)      | (mm)      | (%)        | content |
|             | (mg)      |             |           |            | (%)     |
| F1          | 895.03    | 7.52        | 9.80      | 0.50       | 97.20   |
| F2          | 885.70    | 6.40        | 9.10      | 0.20       | 95.40   |
| F3          | 900.30    | 7.30        | 9.35      | 0.70       | 98.33   |
| F4          | 895.30    | 8.10        | 9.01      | 0.85       | 96.40   |
| F5          | 901.10    | 8.40        | 9.10      | 0.70       | 95.60   |
| F6          | 900.20    | 9.50        | 9.5       | 0.60       | 94.65   |


 Table 8 Post Compression Parameters of Tablet


**Uniformity of drug content:** The uniformity in drug content is an important measure. It gives the percent per unit dosage form. The content uniformity was found within 98.0%-101.0% of 900 mg of Metformin Hydrochloride tablets. Hence the prepared tablets showed good content uniformity.

| Percent Cummulative Drug Release |            |      |       |      |      |      |  |
|----------------------------------|------------|------|-------|------|------|------|--|
| Time(hrs)                        | Batch Code |      |       |      |      |      |  |
|                                  | F1         | F2   | F3    | F4   | F5   | F6   |  |
| 0.5                              | 7.1        | 3    | 8.3   | 3.1  | 5.1  | 4.5  |  |
| 1                                | 11.5       | 6.3  | 15.23 | 8.3  | 7.4  | 9.2  |  |
| 2                                | 19.6       | 11.9 | 24.76 | 10.8 | 8.7  | 18.6 |  |
| 3                                | 28.7       | 20.5 | 35.56 | 21.6 | 28   | 20.8 |  |
| 4                                | 32.8       | 25.8 | 44.76 | 28.7 | 37.6 | 33.4 |  |
| 5                                | 39.7       | 30.5 | 54.76 | 34.3 | 43.8 | 41.8 |  |
| 6                                | 44.5       | 35.8 | 62.65 | 46.8 | 51.4 | 50.3 |  |
| 7                                | 53.6       | 38.5 | 69.67 | 49.2 | 63.4 | 58.6 |  |
| 8                                | 62.7       | 47.8 | 76.45 | 55.8 | 75.4 | 64.5 |  |
| 9                                | 70.8       | 55.4 | 80.5  | 61.3 | 75.4 | 73.8 |  |
| 10                               | 80.1       | 64.7 | 86.3  | 66.8 | 89.6 | 81.7 |  |
| 11                               | 85         | 84.6 | 90.6  | 87.3 | 93.1 | 88   |  |
| 12                               | 90         | 95   | 98    | 91   | 97   | 94   |  |









#### Figure 5 Zero order graph for F6 formulation

#### Discussion

The release profile of formulation F1, F2, F3, F4, F5, F6, comprising polymers like bhara gum gum Karaya with varying concentration. Formulations F1, F2, F3, F4, F5, and F6 exhibits release rates of 90%, 95%, 98%, 91%, 97%, 94%, at various time intervals as shown in the table. Among all of these 6 formulation F3 contains bhara gum shows maximum drug release at the end of 12hrs. Hence it was optimized and decided to develop further formulation. In the present work an attempt was made to formulate sustained release matrix tablet of Metformin hydrochloride utilizing natural gums by wet granulation technique, the identity of Metformin hydrochloride was confirmed by the physical characteristics, spectrometric analysis and FTIR spectra and thermal behavior like melting point, also the selection and isolation of natural polymers like Bhara gum and Gum karaya and then compatibility study between drug and polymer were carried out by FTIR spectrophotometer and no interactions was found. For the preparation of matrix tablet, granules were prepared and they are evaluated for properties like bulk density, tapped density, Hausner ratio, Carr's index and angle of repose. The six formulations were developed by varying the concentration of Natural Polymers (binder) Bhara gum & Gum karaya (10%, 15%, and 20%) As the concentration of polymer (Bhara gum & Gum karaya) increased in the formulation, the hardness is increased by reducing the friability and also drug release time was increased. Formulation F3 exhibits better performance for the tablet properties and drug release. **Conclusion:** From the results and discussion of formulation development and evaluation of sustained release

matrix tablet of Metformin hydrochloride, it was concluded that Bhara gum and Gum karaya possess potential of sustaining the drug release for 12 hours at 20% concentration in the tablet. According to study and results Bhara gum is more superior to Gum karaya.

#### REFERENCES

- Merkus, F.W., 1986. Controlled and rate-controlled drug delivery, principal characteristics, possibilities and limitations. In Struyker-Boudier, H.A. (ed.) Rate Controlled Drug Administration and Action. Boca Raton, FL: CRC Press, pp.15-47.
- Brahmankar, D.M. and Jaiswal, S.B., 2009. Biopharmaceutics and Pharmacokinetics: A Treatise. Vallabh Prakashan, India, p. 41.
- Lin, W. & Metters, J.P., 2006. Design and evaluation of prolonged release gliclazide matrix tablet. Journal of Pharmaceutical Research, 16.
- 4. Modi, S.A., Gaikwad, P.D., Bankar, V.H. and Pawar, S.P., 2011. Sustained release drug delivery system: a review. International Journal of Pharma Research and Development, 2(12), pp.147-160.
- 5. Lankalapalli, S. and Sandhala, D., 2019. A review on natural gums and their use as pharmaceutical excipients. International Journal of Pharmaceutical Sciences and Research, 10(12), pp. 5274-5283.
- Prakash, P. & Porwal, M., 2011. Role of Natural Polymers in Sustained Release Drug Delivery System. *ISSN 2230-8407*, 2(9), pp.6-11.
- 7. Kadri, B.V., 2001. Mechanism of Drug Release from Matrix Tablets Involving Moving Boundaries.

Master of Science. Department of Pharmaceutical Sciences, University of Toronto.

- 8. Jaimini, M. & Kothari, A., 2012. Sustained Release Matrix Type Drug Delivery System: A Review. *Journal of Drug Delivery & Therapeutics*, 2(6), pp.142-148.
- Baravaliya, S.H. & Tandel, J.G., 2013. Analytical Method Development of Repaglinide Formulation. In: Mohite, M.T. et al., *IJRAP*, 4(1).
- El Maghraby, G.M. & Osman, M.A., 2014. Self-Emulsifying Liquid Solid Tablets for Enhanced Oral Bioavailability of Repaglinide: In Vitro and In Vivo Evaluation. *Journal of Applied Pharmaceutical Science*, 4(09), pp.012-021.
- 11. Mutalik, S. & Manoj, K., 2008. Chitosan and Enteric Polymer Based Once Daily Sustained Release Tablets of Aceclofenac. *AAPS PharmSciTech*, 9(2), pp.651-659.
- Saptarshi, D., & Gupta, M. S. (2009). Modified Release Dosage Form and Drug Delivery. Journal of Pharmacy Research, 2(11), 1728-1729.
- 13. Ansel, H.C., Allen, L.V. & Popovich, N.C., 2000. *Pharmaceutical Dosage Forms and Drug Delivery Systems*. 7th ed. Baltimore: Lippincott Williams and Wilkins, pp.231-75.
- James, S., & James, C. (1997). Boylan Encyclopedia of Pharmaceutical Technology (4th Ed.). Marcel Dekker, pp. 304-307.
- Thomas, W.Y. & Joseph, L., 1978. Sustained and Controlled Release Drug Delivery System. *Marcel Dekker*, 6, pp.132-34.
- 16. Periloli, L., Ambrogi, V., et al., 2007. Mucoadhesive Bilayered Tablets for Buccal Sustained Release of Flurbiprofen. *AAPS PharmSciTech*, 8(3), p.54.
- 17. Llabot, J.M., Manzo, R.H., et al., 2002. Double-Layered Mucoadhesive Tablets Containing Nystatin. *AAPS PharmSciTech*, 3(3), p.22.
- Narendra, et al., 2006. Optimization of Bilayer Floating Tablet Containing Metoprolol Tartrate as a Model Drug for Gastric Retention. *AAPS PharmSciTech*, 7(2), p.34.
- 19. Patel, V.M., Bhupendra, G., et al., 2007. Mucoadhesive Bilayer Tablets of Propranolol Hydrochloride. *AAPS PharmSciTech*, 8(3), p.77.
- 20. Patra, C.N. & Kumar, A.B., 2007. Design and Evaluation of Sustained Release Bilayer Tablets of Propranolol Hydrochloride. *Acta Pharmaceutica*, 57, pp.479-489.
- Sonara, G. S., Jaina, D. K., et al. (2007). Preparation and In Vitro Evaluation of Bilayer and Floating-Bioadhesive Tablets of Rosiglitazone Maleate. Asian Journal of Pharmaceutical Science, 2(4), 161-169.
- 22. Krajacic, A., 2003. Matrix Formation in Sustained Release Tablets with Possible Mechanism of Dose Dumping. *International Journal of Pharmaceutics*, 251, pp.67-78.